Voya Investment Management LLC Increases Stock Holdings in Sanofi $SNY

Voya Investment Management LLC raised its stake in Sanofi (NASDAQ:SNY) by 11.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 206,635 shares of the company’s stock after purchasing an additional 21,540 shares during the period. Voya Investment Management LLC’s holdings in Sanofi were worth $11,460,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in SNY. Brighton Jones LLC increased its stake in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Sanofi by 2.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,503 shares of the company’s stock valued at $2,339,000 after purchasing an additional 1,235 shares during the last quarter. Zimmer Partners LP grew its position in shares of Sanofi by 21.3% during the fourth quarter. Zimmer Partners LP now owns 488,300 shares of the company’s stock worth $23,551,000 after acquiring an additional 85,800 shares during the last quarter. Waverly Advisors LLC grew its position in shares of Sanofi by 71.5% during the fourth quarter. Waverly Advisors LLC now owns 9,790 shares of the company’s stock worth $472,000 after acquiring an additional 4,082 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC purchased a new position in shares of Sanofi during the fourth quarter worth approximately $502,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $46.86 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The stock has a fifty day moving average price of $48.58 and a 200 day moving average price of $51.03. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The company has a market cap of $115.07 billion, a PE ratio of 11.26, a P/E/G ratio of 1.10 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same period last year, the business posted $1.73 EPS. Sanofi’s revenue was down 7.0% compared to the same quarter last year. Sell-side analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Guggenheim restated a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Finally, Barclays restated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Sanofi currently has an average rating of “Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.